SGX942 Decreases Duration of Severe Oral Mucositis in Patients with Head and Neck Cancer

TOP - November 2016, Vol 9, No 4 - Supportive Care
Meg Barbor, MPH

Adelaide, Australia—SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research led by Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer, Soligenix, Princeton, NJ, and Mahesh R. Kudrimoti, MD, Professor of Radiation Medicine, University of Kentucky, Lexington.

They presented the results of this double-blind, placebo-controlled, phase 2 exploratory study at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.

SGX942 is a first-in-class innate defense regulator containing the active ingredient dusquetide. According to Dr Donini, its novel mechanism of action modulates the innate immune system to decrease inflammation and enhance bacterial clearance and tissue healing. Chemoradiation-associated oral mucositis has been linked to dysfunctional inflammation stimulated by innate immunity.

Patients with head and neck cancer undergoing chemoradiation are at a particularly high risk for ulcerative (World Health Organization [WHO] score ≥2) and severe (WHO score ≥3) oral mucositis, and severe oral muco­sitis can cause the interruption of chemoradiation in addition to negatively impacting the quality of life of these patients.

A total of 111 patients with head and neck cancer receiving ≥55 Gy radiation and cisplatin (at a dose of 30-40 mg/m2 weekly or 80-100 mg/m2 every third week) were enrolled in the study. Participants received placebo (n = 43) or SGX942 1.5 mg/kg (n = 41) or 6.0 mg/kg (n = 24) twice weekly with a 4-minute intravenous infusion. Oral mucositis was monitored twice weekly until the end of radiation, and then weekly for 1 month. Key efficacy end points included incidence and duration of severe oral mucositis.

An Effective Dose

Patients with higher incidence of severe oral mucositis had a greater benefit from SGX942, although a reduced duration of ulcerative oral mucositis was also observed. Depending on the type of chemoradiation received, the 1.5-mg/kg dose decreased the duration of severe oral mucositis by 50% and 67% among patients at highest risk. The drug did not interfere with tumor treatment, and tumor status at the 1-month follow-up visit favored the 1.5-mg/kg treatment group. Nonfungal infections also decreased in the patients receiving SGX942.

Findings in the 1.5-mg/kg group were consistent across end points (ie, incidence, onset, and duration of severe oral mucositis) and subpopulations (eg, human papillomavirus negative or positive, chemotherapy type): in comparison, the 6.0-mg/kg dose was less effective and inconsistent. A similar, nonlinear dose response curve was observed in the clinical and preclinical phase 1 studies.

The investigators found the drug to be safe and well-tolerated among patients with head and neck cancer, and no treatment-emergent changes were observed in vital signs, laboratory values, adverse events, or serious adverse events between the treatment groups. The findings were consistent with those of the phase 1 clinical study.

This exploratory study confirmed the effective dose of SGX942 in patients with head and neck cancer who have severe oral mucositis, but these results support further clinical research on its effectiveness in oral mucositis, the investigators said.

Related Items
Addressing Usability Concerns in Oncology Electronic Health Records
Meg Barbor, MPH
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Best Practices
New Drug Therapies for Relapsed or Refractory Multiple Myeloma
Meg Barbor, MPH
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Multiple Myeloma
Evidence Supports the Use of Aspirin for Precision Chemoprevention of Colorectal Cancer
Meg Barbor, MPH
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Colorectal Cancer
AONN+ Regional Meeting Addresses the Rapidly Evolving Role of the Navigator
Meg Barbor, MPH
TON - July 2017, Vol 10, No 4 published on July 6, 2017 in Conference Correspondent
A Taxing Consequence: Taxane Acute Pain Syndrome
Mark L. Zangardi, PharmD, BCOP
JHOP - June 2017 Vol 7, No 2 published on May 30, 2017 in Supportive Care, Symptom Management Overview
Helping Adolescents and Young Adults Confront Mortality
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Supportive Care
Multidisciplinary Oral Chemotherapy Clinic Leads to Positive Changes in a Community Hospital
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Best Practices
Effectively Communicating with Older Adults with Cancer
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Best Practices
Complexity Associated with Near Miss or Safety Incidents in Patients Treated with Radiotherapy
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Best Practices
The Emerging Conversation About Physician-Assisted Death
Meg Barbor, MPH
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Supportive Care
Last modified: January 9, 2017